Taming molecular flexibility to tackle rare diseases

Area of Science:

• Biochemistry
• Genetics
• Computational Biology

Background:

• Fabry disease is caused by mutations in the lysosomal alpha-galactosidase gene.
• Many disease-causing mutations destabilize the enzyme but retain some activity, leading to milder phenotypes.
• These milder forms are potential candidates for pharmacological treatments like chaperone therapy or proteostasis modulation.

Purpose of the Study:

• To demonstrate the effectiveness of molecular dynamics (MD) simulations in correlating genotype with Fabry disease severity.
• To investigate the relationship between protein flexibility and residual enzymatic activity of pathological alpha-galactosidase mutants.
• To assess the diagnostic utility of MD simulations for predicting disease phenotype.

Main Methods:

• Utilized molecular dynamics simulations to analyze the structural and dynamic properties of alpha-galactosidase mutants.
• Correlated observed protein flexibility with in vitro and in vivo enzymatic activity data.
• Examined the impact of mutation location on protein stability and residual enzyme function.

Main Results:

• MD simulations effectively correlated genotype with disease severity.
• Mutations located at flexible regions of alpha-galactosidase were found to likely retain enzymatic activity in vivo.
• A strong link was observed between increased protein flexibility and preserved enzyme function.

Conclusions:

• Molecular dynamics simulations are a valuable tool for understanding genotype-phenotype correlations in Fabry disease.
• Protein flexibility is a key determinant of residual enzymatic activity for certain alpha-galactosidase mutants.
• The diagnostic and therapeutic insights from MD simulations extend beyond Fabry disease to other genetic disorders caused by destabilizing mutations.